A total of 68 articles were included in the final synthesis (corresponding to the reference list), comprising clinical trials and observational studies of GLP-1RA, mechanistic and immunology papers on GLP-1 signaling and metabolic inflammation, literature on autoimmune thyroid disease pathophysiology, adipokines, Non-alcoholic fatty liver disease (NAFLD)/Metabolic dysfunction-associated fatty liver disease (MAFLD)/Metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic dysfunction-associated steatohepatitis (MASH), and gut-thyroid-microbiota interactions
16, 2025 from Mozaffarian, D., Agarwal, M., Aggarwal, M., et al
GLP-1 medications have been a hot topic lately, its likely youve even seen a commercial on TV
Some patients report four weeks on semaglutide with no weight loss during the initial dose-titration period, which is often normal and resolves as the dose increases